Upload
rms
View
213
Download
1
Embed Size (px)
Citation preview
60 SECONDS
Bluetongue vaccine catch
As bluetongue spreads across northern
Europe’s farms, carried by midges,
agriculture ministers are calling for
vaccination against the deadly animal
disease. However, the plant where
vaccine is manufactured in the UK by
Merial, at Pirbright, Surrey, has
suspended all work with live viruses
following an escape of foot and mouth
disease virus from the site in August.
Blue whale blues
Three blue whales have died off the
coast of southern California in less than
two weeks. Post-mortems showed that
ships had hit two of them, killing one
instantly. Samples from the third are
still being analysed, but the algal
poison domoic acid is suspected.
Meditation dulls distress
People with rheumatoid arthritis who
practised meditation for six months
experienced a 35 per cent reduction in
psychological distress compared with
those who did not meditate, a study at
the University of Maryland School of
Medicine has found (Arthritis Care & Research, DOI: 10.1002/art.23010).
Meditation did not stop the disease
progressing, as gauged by reports of
swollen joints.
Montreal ozone boost
HCFCs, refrigerant chemicals that
damage the upper atmosphere’s ozone
layer and accelerate global warming,
are to be phased out 10 years earlier
than planned, thanks to an agreement
signed on 22 September. It updates the
20-year-old Montreal protocol to
protect the ozone layer. Industrialised
countries agreed to phase out
HCFCs by 2020, and developing
countries by 2030.
Black hole detector
NASA has restarted NuSTAR, the Nuclear
Spectroscopic Telescope Array project,
cancelled in 2006. Now due to launch in
2011, NuSTAR will detect high-energy
X-rays, providing 500 times the sensitivity
of previous instruments looking for
black holes in the local universe.
director, says the immediate
effect of a ban on spending would
be small but symbolic: “If it stays
for multiple years, it’s going to
turn into a moon programme.”
Hundreds of people have used the
society’s website to tell Congress
they support a crewed Mars flight.
It is not clear who inserted the
banning provision into the House
budget, but Dave Obey, the
Wisconsin Democrat who chairs
the House Appropriations
Committee, supported a ban that
was outvoted in the Republican-
controlled House last year. The
Moon-Mars programme was
proposed by President Bush in
2004. Democrats now control
both the House and Senate.
DRUG companies will in future
find it harder to bury the results
of trials that show their products
in a poor light. The US Food and
Drug Administration (FDA)
Amendments Act, passed by
Congress last week, will require
clinical trials to be registered
and their results placed in a
public database.
The new law contains a raft of
measures to improve drug safety,
including better monitoring for
adverse effects after drugs hit the
market. The trials registry is vital,
says Merrill Goozner of the Center
for Science in the Public Interest
in Washington DC, because
problems such as the heart attack
risk posed by the diabetes drug
Avandia may only come to light
when independent researchers
reanalyse the results of multiple
clinical trials (see page 10).
The FDA will also have to give
the reasons for its decisions on
new drug applications, noting
dissenting scientific opinions. “For
us, this is huge,” says Francesca
Grifo of the Union of Concerned
Scientists in Washington DC,
which last year revealed that
many FDA staff felt their work was
subject to political interference .
But the act fails to impose new
restrictions on drug advertising
and continues to allow the FDA’s
budget to be part-paid by industry.
A POTENTIAL anti-cancer
treatment that attracted massive
public interest earlier this year
is to be tested on 50 people with
brain tumours.
The drug, dichloroacetate
(DCA), disables the energy-
producing mechanism in
cancerous cells, although
concerns remain over toxicity and
side effects such as nerve damage.
Promising results from animal
studies at the University of
Alberta in Edmonton, Canada
(New Scientist, 20 January, p 13)
led to attempts by desperate
cancer patients to buy DCA – a
common lab chemical – online.
The US Food and Drug
Administration later halted sales
of the unapproved drug .
The Canadian researchers,
meanwhile, sought permission
from Health Canada to carry out
an authorised trial – and now
they have it. “We’ve obtained
human ethics approval as well,
and we plan to start immediately,”
says lead researcher Evangelos
Michelakis. The team has so far
raised $800,000 in public
donations to fund the trial.
“We have approval and plan to start trials of dichloroacetate in people immediately”
Thousands of American athletes,
bodybuilders and amateur sports
enthusiasts were sitting in nervous, if
pumped, anticipation this week, as US
federal investigators announced they
had cracked a huge global racket
supplying black-market anabolic
steroids, human growth hormone and
insulin growth factor.
The evidence they seized includes
emails and invoices which could
implicate customers, some of whom
may be leading athletes.
Nationwide raids on 24 September
by officials from the US Drug Enforcement
Administration led to 124 arrests at 56
steroid labs. Agents seized 242 kilograms
of raw steroid powder, mainly of Chinese
origin, and 11.4 million doses of steroids.
With collaborators in nine other
countries, Operation Raw Deal
uncovered a clandestine web of
international drug dealers selling
through the internet. Much of the
merchandise was produced in garages,
bathtubs and sinks. The DEA announced:
“Today we reveal the truth behind the
underground steroid market: dangerous
drugs cooked up all too often in filthy
conditions with no regard to safety.”
The global sting focused on
underground labs in the US, Canada
and Mexico, and numerous US-based
websites. Investigators located many
illicit sellers by visiting bodybuilding
discussion websites, where enthusiasts
can learn how to make steroids from
raw materials at home. Besides steroids,
the seizures included the stimulants
ephedrine and pseudoephedrine.
STING SMASHES STEROID RACKET
M. L
. SIN
IBAL
DI/C
ORBI
S
–Tense moments–
No hiding place
Cancer trial is go
www.newscientist.com 29 September 2007 | NewScientist | 5
070929_N_Upfronts.indd 5070929_N_Upfronts.indd 5 25/9/07 4:56:15 pm25/9/07 4:56:15 pm